Determine the Effect of Administering Periostat(R) Twice Daily on Patients With Acne Rosacea
This study has been completed.
First Posted: July 23, 2002
Last Update Posted: December 9, 2005
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Information provided by:
The purpose of this study is to determine whether Periostat(R), Doxycycline Hyclate 20 mg Tablets, taken twice daily is effective in reducing the red and white heads and overall redness associated with rosacea.
Drug: doxycycline hyclate 20 mg twice daily
Intervention Model: Single Group Assignment
Primary Purpose: Treatment
||A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Determine the Effects of Doxycycline Hyclate 20 Mg Tablets [Periostat(R)] Administered Twice Daily for the Treatment of Acne Rosacea
| Estimated Enrollment:
| Study Start Date:
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:
||18 Years and older (Adult, Senior)
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
- Healthy, post-pubescent male and females > age 18, with rosacea, 10 to 30, [papules and pustules] and < 2 nodules.
- Presence of moderate to severe erythema.
- Presence of telangiectasia.
- Female patients must utilize one of the following methods of birth control throughout the study: IUD, diaphragm, a condom plus the use of a spermicidal gel or foam, oral contraceptives (provided patient has been utilizing this method for at least 4 months prior to baseline and has not changed the brand within this period). Patients may also participate if they are surgically sterilized, in a monogamous relationship with a sterile partner, or sign an agreement that they will abstain from sexual intercourse during the course of a study.
- Patients must sign an informed consent form.
- Negative pregnancy test and non-lactating.
- The initiation of a hormonal method of contraception within 4 months of baseline; or discontinuation during the course of study; or change in the actual product within 4 months of baseline or during the study.
- The use of topical acne treatments within 2 weeks of baseline.
- The use of systemic antibiotics within 4 weeks of baseline.
- The use of an investigational drug with 90 days of baseline.
- Pregnant women or women of child-bearing potential who are not using an adequate form of birth control as described in Item 4 of the Inclusion Criteria.
- Nursing women.
- Patients with a known hypersensitivity to tetracyclines.
- Patients on clinically significant, concomitant drug therapy (See section below).
- The use of any acne treatment during the course of the study.
- The use of topical steroids 6 weeks prior to baseline and during the study.
- The use of systemic corticosteroids 6 weeks prior to baseline and during the study.
- The use of vasodilators 6 weeks prior to baseline or during the study.
- The use of α-adrenergic receptor-blocking agents 6 weeks prior to baseline and during the study.
- Chronic use (> 14 days) of sulfa drugs, erythromycin, cephalosporins, and quinolones.
- The use of tetracycline antibiotics is prohibited.
- Use of any acne treatment during the course of the study, including spironolactone.
- Chronic use (> 14 days) of NSAIDs. Chronic use of aspirin at sub-analgesic doses (< 325 mg q.d.) may be used by those patient requiring platelet aggregation inhibitor.
- Penicillin antibiotics should NOT be used during the course of this trial since the bacteriostatic action of doxycycline may interfere with the bactericidal action of penicillins.
- Antacids and vitamins containing aluminum, calcium, or magnesium may impair drug absorption and should be taken at least 1.5 hours before or 3.0 hours after taking study medication.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00041977
|University of Florida
|Gainesville, Florida, United States, 32610 |
|University of Miami Medical Center
|Miami, Florida, United States, 33136 |
|Beer and Houck/Florida Dermatology Institute
|West Palm Beach, Florida, United States, 33104 |
|University of Louisville
|Louisville, Kentucky, United States, 40202 |
|Milton S. Hershey Medical Center
|Hershey, Pennsylvania, United States, 17033 |
|University of Pennsylvania
|Philadelphia, Pennsylvania, United States, 19104 |
|David Pariser, MD
|Norfolk, Virginia, United States, 23507 |
History of Changes
|Other Study ID Numbers:
||July 19, 2002
||July 23, 2002
|Last Update Posted:
||December 9, 2005
Keywords provided by CollaGenex Pharmaceuticals:
Additional relevant MeSH terms: